Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19 - 30/11/21
, Fred Blind, MD a, Andrew Barbera, MD a, Donna Bhisitkul, MD b, Shannon Hasara, PharmD a, Karen Homa, PhD c, Juliana Karp, MD a, Hal Escowitz, MD a, Todd Haber, MD a, Diana DeGroot, DNP, RN a, Jonathan Anderson, MD a, Jason DeLeon, MD a, Jesse De Los Santos, MD a, Donna Faviere, DNP, RN a, Joanne Fuell, MN, RN a, Rita Gillespie, DO a, Jesse Glueck, MD a, Cliff Reeber, MD a, David J. Rhodes, MD b, Vashun Rodriguez, MD a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Recombinant monoclonal antibody therapies have been utilized under emergency use authorization (EUA) for the prevention of clinical decompensation in high-risk COVID-19 positive patients for up to 10 days from symptom onset. The purpose of this study was to determine the impact of the timing of the monoclonal antibody, bamlanivimab, on clinical outcomes in high-risk COVID-19 positive patients.
Methods |
This was an IRB-approved, retrospective evaluation of adult patients who received bamlanivimab per EUA criteria in the emergency department (ED). Patients were dichotomized into two groups– 3 days of symptoms or less (early) versus 4 to 10 days (late). The primary outcome was hospitalization for COVID-related illness at 28 days (or treatment failure). Secondary outcomes were COVID-related ED visits at 28 days, hospital and intensive care unit (ICU) length of stay (LOS), and in-hospital mortality at 28 days.
Results |
A total of 839 patients were included in the analysis. There was no difference observed in COVID-related hospitalization rates within 28 days between the early and late bamlanivimab administration groups (7.5% vs. 8.2%, p = 0.71). There was no difference in COVID-related ED visits within 28 days with 13% of patients returning to the ED.
Conclusions |
In conclusion, there were no differences in the rates of hospitalization at 28 days when bamlanivimab was administered in the first 3 days of illness versus days 4 to 10. Future prospective studies are warranted to expand upon the characteristics of patients that may or may not benefit from monoclonal antibody therapy.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Monoclonal antibody therapy, Bamlanivimab, High-risk COVID-19
Plan
Vol 50
P. 437-441 - décembre 2021 Retour au numéro
Article précédent
- Prevalence of myocardial infarction among patients with chest pain and cocaine use: A systematic review and meta-analysis
- Jennifer Wang, Priya S. Patel, Sanketh Andhavarapu, Vera Bzihlyanskaya, Eric Friedman, Maniraj Jeyaraju, Jamie Palmer, Alison Raffman, Ali Pourmand, Quincy K. Tran
- Dexmedetomidine in combination with ketamine for pediatric procedural sedation or premedication: A meta-analysis
- Hong-pei Li, Kun-peng Liu, Lan Yao
Bienvenue sur EM-consulte, la référence des professionnels de santé.